Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476570 | 0.90 | GPR119 (0.47) | GPR119HDAC4HDAC6HDAC1HDAC8 | |
| SCHEMBL4096906 | 0.88 | GPR119 (0.76) | GPR119HDAC4MMP13 | |
| SCHEMBL4095580 | 0.86 | GPR119 (0.58) | GPR119HDAC4HDAC6ALOX5APFEN1 | |
| SCHEMBL4101081 | 0.86 | GPR119 (0.78) | GPR119HDAC4 | |
| SCHEMBL4103540 | 0.86 | GPR119 (0.78) | GPR119HDAC4 | |
| SCHEMBL4102772 | 0.86 | GPR119 (0.78) | GPR119HDAC4 | |
| SCHEMBL4097038 | 0.84 | GPR119 (0.63) | GPR119HDAC4HDAC6MMP13HDAC1 | |
| SCHEMBL4101075 | 0.82 | GPR119 (0.53) | GPR119HDAC4HDAC6MMP13 | |
| SCHEMBL4412537 | 0.80 | GPR119 (0.51) | GPR119HDAC4HDAC6MMP13HDAC1 | |
| SCHEMBL4416595 | 0.80 | GPR119 (0.69) | GPR119HDAC4HDAC6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | claimed |
| EP-2013201-B1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LTD (GB) | 2012-07-25 | — | — | EP | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221639-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GLP1R | GPR119 1/4885HDAC4 2035/4885HDAC6 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.